Effectiveness of arsenious acid combined with CTD chemotherapy in the treatment of relapsed and refractory multiple myeloma

PAN Chenglin; LI Hujun; YAN Zhiling; YAO Yao; YAO Ruosi; LI Yanjie; XU Kailin; LI Zhenyu

doi:10.3969/j.issn.2096-3882.2022.02.006

Journal of Xuzhou Medical University > 2022 > 42(2): 106-109. > DOI: 10.3969/j.issn.2096-3882.2022.02.006

PAN Chenglin, LI Hujun, YAN Zhiling, YAO Yao, YAO Ruosi, LI Yanjie, XU Kailin, LI Zhenyu. Effectiveness of arsenious acid combined with CTD chemotherapy in the treatment of relapsed and refractory multiple myeloma[J]. Journal of Xuzhou Medical University, 2022, 42(2): 106-109. DOI: 10.3969/j.issn.2096-3882.2022.02.006

Citation:

PDF (1873 KB)

Effectiveness of arsenious acid combined with CTD chemotherapy in the treatment of relapsed and refractory multiple myeloma

Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

More Information

Received Date: May 12, 2020
Revised Date: January 05, 2022

Graphical Abstract

Abstract

Abstract

Objective To investigate the therapeutic effect and adverse events of arsenious acid combined with cyclophosphamid, thalidomide and dexamethasone (CTD) chemotherapy in the treatment of relapsed and refractory multiple myeloma (MM). Methods A total of 32 relapsed and refractory MM patients who received arsenious acid combined with CTD chemotherapy were enrolled and their clinical data were retrospectively analyzed. Their overall survival rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and adverse reactions were analyzed. Results All patients were evaluated for their therapeutic effects, with ORR of 50% (16/32) and CBR of 62.5% (20/32). For 15 patients who received arsenious acid combined with CTD chemotherapy due to the presence of progression after bortezomib-based therapy, their ORR was 53.3% (8/15), and CBR was 80.0% (12/15). The median follow-up time of these 32 patients was 10 (3—33) mouths. At the end of follow-up visit, 20 patients survived, and the median PFS and OS was 6.0 (95%CI 4.52—7.48) and 24.0 (95%CI 17.14—30.85), respectively. The main adverse reactions were digestive tract reaction, leukocytopenia, liver function damage, and peripheral neuropathy. Conclusions Arsenious acid combined with CTD chemotherapy is a good choice of treatment for some relapsed and refractory MM patients, and effective for bortezomib resistant MM patients to some extent.
- arsenious acid,
- cyclophospamide,
- relapsed and refractory multiple myeloma

FullText(HTML)

References (15)

References

[1]	Mateos MV,San Miguel JF.Bortezomib in multiple myeloma[J].Best Pract Res Clin Haematol,2007,20(4):701-715.
[2]	Gozzetti A,Candi V,Papini G,et al.Therapeutic advancements in multiple myeloma[J].Front Oncol,2014,4:241.
[3]	Matulis SM,Morales AA,Yehiayan L,et al.Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma[J/OL].PLoS One,2012,7(12):e52662.
[4]	Steven H,Eliu S,Lee N,et al.Plasma cell neoplasms.WHO classification of tumors of haematopoietic and lymphoid tissues[M].Lyon:International Agency for Research on Cancer,2008:200-213.
[5]	Bladé J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant[J].Br J Haematol,1998,102(5):1115-1123.
[6]	Mathews V,George B,Lakshmi KM,et al.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:durable remissions with minimal toxicity[J].Blood,2006,107(7):2627-2632.
[7]	Lou YJ,Suo SS,Tong Y,et al.Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy[J].Ann Hematol,2014,93(6):941-948.
[8]	Kritharis A,Bradley TP,Budman DR.The evolving use of arsenic in pharmacotherapy of malignant disease[J].Ann Hematol,2013,92(6):719-730.
[9]	Takahashi S.Combination therapy with arsenic trioxide for hematological malignancies[J].Anticancer Agents Med Chem,2010,10(6):504-510.
[10]	Kluck RM,Bossy-Wetzel E,Green DR,et al.The release of cytochrome c from mitochondria:a primary site for Bcl-2 regulation of apoptosis[J].Science,1997,275(5303):1132-1136.
[11]	Kapahi P,Takahashi T,Natoli G,et al.Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase[J].J Biol Chem,2000,275(46):36062-36066.
[12]	Wang Y,Fang MY.Effect of ginseng saponin,arsenic trioxide,beta-elemene combined with CTX on telomere-telomerase system in K562 cell line[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2006,14(6):1089-1095.
[13]	Li X,Sun WJ.The clinical activity of arsenic trioxide,ascorbic acid,ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma[J].Onco Targets Ther,2015,8:775-781.
[14]	Wen JG,Feng YD,Huang WT,et al.Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition[J].Leuk Res,2010,34(1):85-92.
[15]	QianWS,Wang L,Li P,et al.Efficiency and tolerability of induction and consolidation therapy with arsenic trioxide/bortezomib/ascorbic acid/dexamethasone (ABCD) regimen compared to bortezomib/dexamethasone (BD) regimen in newly diagnosed myeloma patients[J].Cancer Manag Res,2020,12:431-441.

Cited By

Get Citation

PDF

XML

Article views (924) PDF downloads (604)

Turn off MathJax

Article Contents

Abstract

References

Effectiveness of arsenious acid combined with CTD chemotherapy in the treatment of relapsed and refractory multiple myeloma

Abstract

References

Catalog

Export File

Citation

Format

Content